What's the mechanism of action for tucatinib?
Tucatinib (Tukysa) is a human epidermal growth factor receptor-2 (HER2) inhibitor that works by blocking the HER2 protein to help slow or stop cancer cell growth in patients with advanced breast cancer or colorectal cancer. Some cancers have an over-expression of the HER2 protein causing increased growth and spread of cancer cells.
Tucatinib, an oral targeted drug therapy, is very selective for the HER2 protein and works inside the cell. Tucatinib binds to tyrosine kinase (an enzyme) of HER2, reducing PI3-kinase and MAP-kinase signaling. Reduced signaling helps to block cell growth and leads to cell death. Tucatinib is classified as a HER2 tyrosine kinase inhibitor.
Related information: List of HER2 Inhibitors
How is tucatinib used?
- Tucatinib (Tukysa) is used with the medicines trastuzumab (Herceptin) and capecitabine (Xeloda) in adult patients with HER2-positive breast cancer, including cancer that has spread to the brain. It is given to patients who have already received one or more anti-HER2 breast cancer treatments, but are no longer effective.
- It is also used in combination with trastuzumab to treat adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
- It is used when the cancer has spread in the body (metastatic) or cannot be removed with surgery (unresectable).
The FDA approved Tukysa for colorectal cancer under an "accelerated approval". This means that continued approval for this use may depend upon results of further clinical studies looking at its effectiveness in colorectal cancer.
This is not all the information you need to know about Tukysa (tucatinib) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full product information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related Questions
References
- Tukysa (tucatinib) product information. Seagen. Bothell, WA. Revised 1/2023. Accessed Jan 25, 2023 at https://docs.seagen.com/TUKYSA_Full_Ltr_Master.pdf
- Tukysa.com. Mechanism of Action. Seagen Inc. Accessed April 22, 2021 at https://www.tukysahcp.com/videolibrary
Read next
Related medical questions
- Why are my nipples sore? 7 possible causes
- Does anastrozole cause hair loss?
- What is the success rate of Keytruda?
- What are monoclonal antibodies?
- What does anastrozole do to your body?
- Is letrozole a form of chemotherapy?
- What is the lifetime or cumulative dose for Adriamycin?
- Does Femara make your hair fall out?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- Why give Taxol (Paxel) before carboplatin?
- Does letrozole affect blood sugar levels?
- Will insurance pay for the cost of Ibrance?
- How does AC (Adriamycin and Cytoxan [cyclophosphamide]) work for Breast Cancer?
- What is the success rate for Femara in breast cancer?
- Why do you need to take Xeloda with food?
- Is it common to lose hair AFTER stopping tamoxifen?
- What are the long-term side effects of Adriamycin?
- Which is better - Aromasin or Femara?
- How long can you stay on Herceptin and Perjeta?
- How long do you take Verzenio for?
- How long does Herceptin stay in your body?
- How common is hair loss with Ibrance?
- How does Ibrance kill cancer?
- What is Paxel called in the USA?
- Is Verzenio better than Ibrance?
- Is Ibrance a form of chemo?
- How long can you take Faslodex?
- How effective is Trodelvy?
- What happens after Herceptin treatment?
- Can you take Verzenio after Ibrance fails?
Drug information
Related support groups
- Tucatinib (3 questions, 3 members)
- Tukysa (3 questions, 3 members)
- Breast Cancer (121 questions, 304 members)
- Colorectal Cancer (16 questions, 52 members)